COMPLEX THERAPY OF GASTRODUODENITIS WITH THE SYNDROME OF EXCESSIVE BACTERIAL GROWTH
https://doi.org/10.22627/2072-8107-2018-17-3-46-50
Abstract
The aim of the study was to evaluate the clinical efficacy and safety of the probiotic containing Lactobacillus acidophilus and Kefir grains (Acipol®) in the complex therapy of chronic gastroduodenal diseases with a syndrome of excessive bacterial growth in children aged 6 to 17 years.
We observed 43 children with chronic gastroduodenal diseases associated with Helicobacter pylori infection, accompanied by a syndrome of excessive bacterial growth. Patients were divided into 2 groups: 1 group comprised 28 children who received Acipol 2 weeks on a background of standard therapy, and 2 group (15 people) received standard therapy without Acipol. All children of both groups were assessed pain index, dyspeptic index, hydrogen respiratory test with lactulose, quantitative PCR in feces before treatment, after 2 weeks, after 6 weeks.
After 2 weeks, there was a significant decrease in pain index and dyspeptic index in group 1, by 6 weeks this decline continued. The hydrogen breathing test with lactulose, conducted after 2 weeks, became negative in group 1 in 13 children (46%), and was preserved in 15 (54%). The same result was noted after 6 weeks. That is, elimination of the syndrome of excessive bacterial growth was achieved in 43% of children against the background of Acipol.
About the Authors
E. A. Kornienko
Saint-Petersburg State Pediatric Medical University
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
A. V. Saburova
Saint-Petersburg State Pediatric Medical University
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
References
1. Shenderov B.A. Medical microbial ecology and functional nutrition. M., 1998. (In Russ.)
2. Kau A.L., Ahern P.P., Griffin N.W., et al. Human nutrition, the gut microbiome and the immune system. Nature. 2011; 474:327—336.
3. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. 2005; 51: 1—22.
4. Alderberth I. Factors influencing the establishment of the intestinal microbiota in infancy. Ed.Bier D.M., German J.B., Lonnerdal B.: Personalized Nutrition for the diverse needs of infants and children, Nestle Nutr.Workshop. 2008; 62:13—33.
5. Hawrelak J.A., Myers S.P. The causes of intestinal dysbiosis: a review. Altern. Med. Rev. 2004; 9: 180—197.
6. Parfenov A.I. Clinical problems of dysbacteriosis. Ros. gastroenterol. journal. 1999; 4: 49-55. (In Russ.)
7. Bouhnik Y., Alain S., Attar A. et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am. J. Gastroenterol. 1999; 94:1327—1331.
8. Kovalenko A.A., Gasilina T.V., Belmer S.V. Flatulence: norm and pathology. Therapist. 2008; 2: 38-43. (In Russ.)
9. Koshini R., Dai S.C., Lezcano S. et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig. Dis. Sci. 2008; 53: 1443—1454.
10. Gasbarrini A., Corazza G.R., Gasbarrini G., Montalto M.; 1st Rome H 2 — Breath Testing Consensus Conference Working Group. Methodology and indications of H 2 —breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment. Pharmacol. Ther. 2009, Mar 30. 29 (suppl. 1): 1—49.
Review
For citations:
Kornienko E.A., Saburova A.V. COMPLEX THERAPY OF GASTRODUODENITIS WITH THE SYNDROME OF EXCESSIVE BACTERIAL GROWTH. CHILDREN INFECTIONS. 2018;17(3):46-50. (In Russ.) https://doi.org/10.22627/2072-8107-2018-17-3-46-50
Views:
731
Email this article 